Phase III IMvigor010 trial evaluating atezolizumab for urothelial carcinoma fails to meet primary endpoint

The phase III trial involving 809 patients with muscle-invasive urothelial cancer at high risk of recurrence after surgery did not meet the primary endpoint of disease-free survival (DFS) when compared with no treatment.

Source:

Biospace Inc.